West Pharmaceutical Services, Inc. (WST)
- Previous Close
377.36 - Open
377.49 - Bid --
- Ask --
- Day's Range
372.41 - 380.67 - 52 Week Range
310.42 - 415.73 - Volume
315,058 - Avg. Volume
529,148 - Market Cap (intraday)
27.623B - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
47.82 - EPS (TTM)
7.89 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield 0.80 (0.21%)
- Ex-Dividend Date Apr 23, 2024
- 1y Target Est
400.43
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
www.westpharma.com10,600
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: WST
Performance Overview: WST
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: WST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: WST
Valuation Measures
Market Cap
27.62B
Enterprise Value
27.08B
Trailing P/E
47.88
Forward P/E
49.51
PEG Ratio (5yr expected)
6.68
Price/Sales (ttm)
9.63
Price/Book (mrq)
9.59
Enterprise Value/Revenue
9.18
Enterprise Value/EBITDA
32.07
Financial Highlights
Profitability and Income Statement
Profit Margin
20.12%
Return on Assets (ttm)
11.93%
Return on Equity (ttm)
21.32%
Revenue (ttm)
2.95B
Net Income Avi to Common (ttm)
593.4M
Diluted EPS (ttm)
7.89
Balance Sheet and Cash Flow
Total Cash (mrq)
853.9M
Total Debt/Equity (mrq)
10.73%
Levered Free Cash Flow (ttm)
199.04M
Research Analysis: WST
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: WST
WST: Lowering target price to $398.00
WEST PHARMACEUTICAL SERVICES has an Investment Rating of HOLD; a target price of $398.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingNeutralPrice TargetWST: Raising target price to $412.00
WEST PHARMACEUTICAL SERVICES has an Investment Rating of HOLD; a target price of $412.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingNeutralPrice TargetWST: Lowering target price to $407.00
WEST PHARMACEUTICAL SERVICES has an Investment Rating of HOLD; a target price of $407.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingNeutralPrice TargetWST: Lowering target price to $408.00
WEST PHARMACEUTICAL SERVICES has an Investment Rating of HOLD; a target price of $408.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingNeutralPrice Target